Skip to content

Arrowhead Pharmaceuticals

US · ARWR #1569 by market cap Listed 1970
41.37 -2.28 -5.22%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
  • Total institutional ownership rose 2.8 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
90.87% +2.83pp
Institutions
590 -5
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund61.33%
Hedge Fund16.64%
Public Company5.37%
Individual/Insider3.32%
Sovereign Wealth Fund2.76%
Private Company1.74%
VC/PE Fund1.63%
Government Pension Fund1.00%
Insurance Company0.26%
Other5.96%

Top holders as of 2026-09-30

BlackRock 10.72% · 15.14M sh
Avoro Capital Advisors LLC 8.04% · 11.36M sh
FMR 6.62% · 9.35M sh
Vanguard Portfolio Management, LLC 4.40% · 6.21M sh
State Street Global Advisors 4.33% · 6.12M sh
Vanguard Capital Management, LLC 4.33% · 6.12M sh
Norges Bank Investment Management 2.76% · 3.90M sh
Christopher Anzalone 2.69% · 3.79M sh
Geode Capital Management, LLC 2.45% · 3.46M sh
Fred Alger Management, LLC 2.34% · 3.30M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 12 buys · 37 sells

NameRoleStake
Christopher Anzalone Chairperson & CEO 2.69%
Patrick O'Brien COO & Secretary 0.24%
James Hamilton Chief Medical Officer and Head of R&D 0.16%
Michael Perry Independent Director 0.07%
Mauro Ferrari Independent Director 0.04%
William Waddill Lead Independent Director 0.03%
Hongbo Lu Independent Director 0.03%
Adeoye Olukotun Independent Director 0.02%
Victoria Vakiener Independent Director 0.02%
Daniel Apel Chief Financial Officer 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-08-17 Adeoye Olukotun Independent Director Open Market Disposition -2,000 $86.96
2026-08-17 Michael Perry Independent Director Open Market Disposition -11,600 $87.30
2026-06-14 Matthew Cohen Director Other Acquisition +11,882 --
2026-05-11 Hongbo Lu Independent Director Open Market Disposition -2,970 $76.88
2026-05-11 Hongbo Lu Independent Director Intent to Sell (Form 144) -315,202 --
2026-04-22 James Hamilton Chief Medical Officer and Head of R&D Automatic Disposition -10,000 $75.00
2026-04-22 James Hamilton Chief Medical Officer and Head of R&D Intent to Sell (Form 144) -10,000 --
2026-04-21 Daniel Apel Chief Financial Officer Automatic Disposition -13,095 $70.11–71.92
2026-04-21 Daniel Apel Chief Financial Officer Intent to Sell (Form 144) -13,095 --
2026-03-04 James Hamilton Chief Medical Officer and Head of R&D Automatic Disposition -10,000 $64.19
2026-01-05 Daniel Apel Chief Financial Officer Other Acquisition +75,000 --
2026-01-05 James Hamilton Chief Medical Officer and Head of R&D Other Acquisition +75,000 --
2026-01-05 Patrick O'Brien COO & Secretary Other Acquisition +75,000 --
2026-01-05 Patrick O'Brien COO & Secretary Other Disposition -2,500 --
2026-01-04 James Hamilton Chief Medical Officer and Head of R&D Automatic Disposition -40,164 $61.24–68.00
2026-01-04 James Hamilton Chief Medical Officer and Head of R&D Intent to Sell (Form 144) -40,164 $63.10
2026-01-04 Patrick O'Brien COO & Secretary Automatic Disposition -49,493 $61.12–68.00
2026-01-01 Christopher Anzalone Chairperson & CEO Automatic Disposition -13,187 $65.88–66.39
2025-12-30 Patrick O'Brien COO & Secretary Other Disposition -2,800 --
2025-12-28 Christopher Anzalone Chairperson & CEO Derivative Exercise and Sale -51,726 $6.15–69.33

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Arrowhead Pharmaceuticals discussion 0 comments

Add a comment